Niederer Kraft Frey advised Deutsche Bank, acting as coordinator, HSBC acting as agent and further banks on the Revolving Committed Facility of DKSH Holding. DKSH Holding is a SIX Swiss Exchange listed company specializing in
Tags :Philippe Weber
Niederer Kraft Frey acted as legal counsel to the sales enablement platform for enterprise companies Pitcher on a transaction leading to a strategic growth investment from Crest Rock Partners. Founded in 2011 by Mert Yentür,
Niederer Kraft Frey advised EPIC Suisse as issuer’s counsel in connection with its initial public offering and listing on SIX Swiss Exchange. The transaction represents the first traditional IPO on the Main Market of
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
Climeworks signs an equity round of CHF 600 million (USD 650 million). The financing is co-led by Partners Group (acting on behalf of its clients) and GIC, with further participation from Baillie Gifford, Carbon Removal Partners, Global
Ginkgo Bioworks, a horizontal platform for cell programming, entered into a definitive purchase agreement to acquire FGen, a Swiss company specializing in strain development and optimization. Ginkgo Bioworks believes that FGen’s technology will significantly
On January 31, 2022, FNZ, a global wealth management platform, has completed the acquisition of Appway, the leader in client onboarding and servicing for financial institutions. Homburger acted as Swiss counsel to FNZ in this transaction. The
SIX listed SFS Group has entered into an agreement to join forces with and acquire 100 per cent of Hoffmann. The transaction does not include Contorion, the eCommerce subsidiary of Hoffmann, which is geared towards a
The first Swiss SPAC, VT5 Acquisition Company, successfully priced its initial public offering. The listing of the Class A Shares and Redeemable Warrants on
Draupnir Holding, global provider of business decisioning data and analytics, sells 1,500,000 existing ordinary shares in PolyPeptide Group in private placements to institutional investors by way of an accelerated bookbuilding process. The shares, which represent approximately 4.5
